Group 1 - The company's laboratory services achieved revenue of 8.1589 billion yuan, a year-on-year increase of 15.8% [1] - The gross margin for the year 2025 reached 44.7%, an increase of 0.3 percentage points compared to the previous year [1] - New orders in this segment grew by approximately 12% year-on-year [1] Group 2 - The company expanded multiple strategic partnerships in 2025, making significant progress in large collaborative projects [1] - The laboratory services revenue from biological sciences accounted for over 56% of total revenue [1] - As of December 31, 2025, the company employed 11,776 staff in laboratory services, including over 7,100 laboratory chemists, positioning itself as a leader in scale and experience globally [1] Group 3 - The company participated in 887 global innovative drug discovery projects during the reporting period [1] - The total revenue reported for the year ending December 31, 2025, was 14.095 billion yuan, reflecting a year-on-year growth of 14.8% [2] - The profit attributable to the parent company was 1.664 billion yuan, a decrease of 7.2% year-on-year, with basic earnings per share of 0.9443 yuan [2]

3月31日，康龙化成最新高管薪酬曝光。根据2025年报数据，剔除独立董事、监事会主席、监事后，康 龙化成共有8位董事和高级管理人员。从年龄看，康龙化成董事和高级管理人员平均年龄为54岁，年龄 中位数为55岁，其中，首席科学官（副经理）Hua Yang年龄最高为64岁，非执行董事万璇年龄最小为43 岁。 | Hua Yang | 首席科学官（副经 | 20161027 | - | 391.74 | 200.41 | 64 | | --- | --- | --- | --- | --- | --- | --- | | | 理） | | | | | | | 郑北 | 执行副总裁（副经 理） | 20161027 | - | 360.00 | 200.00 | 59 | | | 执行董事 | 20230621 | 20260620 | | | | | 胡柏风 | 非执行董事 | 20230621 | 20250620 | 0 | - | 45 | | 万璇 | 非执行董事 | 20250620 | 20260620 | 0 | - | 43 | | 李家庆 | 非执行董事 | 20230621 | 20260620 ...

Core Viewpoint - Kanglong Chemical (300759.SZ) reported a revenue of 14.095 billion yuan for the year 2025, reflecting a year-on-year growth of 14.82% while the net profit attributable to shareholders decreased by 7.22% to 1.664 billion yuan [1] Financial Performance - The company achieved an operating income of 14.095 billion yuan, which is a 14.82% increase compared to the previous year [1] - The net profit attributable to shareholders was 1.664 billion yuan, showing a decline of 7.22% year-on-year [1] - The net profit excluding non-recurring gains and losses was 1.538 billion yuan, indicating a significant increase of 38.85% year-on-year [1] Dividend Distribution - The company proposed a dividend of 2 yuan per share to all shareholders [1]

Core Viewpoint - Kanglong Chemical achieved a revenue of 14.095 billion yuan in 2025, representing a year-on-year growth of 14.82%, while the net profit attributable to shareholders decreased by 7.22% to 1.664 billion yuan [1] Group 1 - The company focused on investing in automation and AI technology during the reporting period [1] - These technologies are deeply integrated into various stages of drug research and development [1] - The aim is to enhance experimental throughput, improve service efficiency, and reduce operational errors, providing clients with faster, more accurate, and reliable research data [1]

Core Viewpoint - Kanglong Chemical (03759) has announced that its board has approved a proposal to increase the company's registered capital and amend its articles of association [1] Group 1: Capital Increase - The company plans to increase its registered capital from RMB 1.778 billion (1.778 billion shares) to RMB 1.837 billion (1.837 billion shares) [1] - This increase is attributed to the placement of a total of 58.4408 million new H-shares scheduled for January 22, 2026 [1] - Additionally, 647,300 restricted A-shares from the fourth vesting period of the 2021 A-share incentive plan and the third vesting period of the 2022 A-share incentive plan will be registered and listed for circulation on January 29, 2026 [1] Group 2: Amendments to Articles of Association - The board's proposal includes amendments to the company's articles of association in line with the capital increase [1]

Core Viewpoint - 康龙化成 announced the resignation of Mr. 严洛钧 as the company secretary and authorized representative, effective March 30, 2026, with Ms. 麦宝文 appointed to the position starting the same date [1] Group 1 - Mr. 严洛钧 has resigned from his role as company secretary and authorized representative [1] - The resignation is in accordance with the Hong Kong Stock Exchange Listing Rules and the Companies Ordinance [1] - Ms. 麦宝文 has been appointed as the new company secretary and authorized representative, effective March 30, 2026 [1]

Core Viewpoint - 康龙化成 reported a revenue of 14.095 billion RMB for the year ending December 31, 2025, representing a year-on-year growth of 14.82%, while the net profit attributable to shareholders decreased by 7.2% to 1.664 billion RMB [1] Group 1: Financial Performance - The company announced a proposed final dividend of 2.0 RMB per 10 shares (tax included) for the year ending December 31, 2025 [1] - The revenue growth of 14.82% indicates strong operational performance despite the decline in net profit [1] - The new signed orders increased by over 14% year-on-year, indicating a positive trend in business development [1] Group 2: Strategic Initiatives - The company emphasizes a customer-centric service philosophy and leverages an integrated service platform to meet diverse global client needs [1] - Significant achievements were noted in expanding the client base, particularly with large pharmaceutical companies [1] - The company is actively implementing market strategies tailored to the Chinese market, contributing to rapid growth in client business [1] Group 3: Future Outlook - The company anticipates a revenue growth of 12% to 18% for the year 2026 based on new signed orders and business trends [1] - The company maintains industry leadership in small molecule fields while also achieving rapid development in new molecular type projects [1]

Core Viewpoint - 康龙化成 reported a revenue of 14.095 billion RMB for the year ending December 31, 2025, representing a year-on-year growth of 14.82%, while the net profit attributable to shareholders decreased by 7.2% to 1.664 billion RMB [1] Group 1: Financial Performance - The company's revenue for the fiscal year was 14.095 billion RMB, showing a growth of 14.82% compared to the previous year [1] - The net profit attributable to shareholders was 1.664 billion RMB, which is a decrease of 7.2% year-on-year [1] - The board proposed a final dividend of 2.0 RMB per 10 shares (before tax) for the year ending December 31, 2025 [1] Group 2: Strategic Initiatives - The company is deepening its customer-centric service philosophy and leveraging a fully integrated service platform to meet diverse global client needs [1] - Significant achievements were noted in expanding strategic customer relationships, particularly with large pharmaceutical companies [1] - The company is actively implementing market strategies tailored to the Chinese market, resulting in rapid growth in client business [1] Group 3: Future Outlook - The company expects a year-on-year growth of over 14% in new signed orders for 2025 [1] - Based on new orders and business trends, the company anticipates a revenue growth of 12% to 18% for the year 2026 [1]

Group 1 - The company, Kanglong Chemical (SZ 300759), announced on March 30 that it will hold the 19th meeting of the third board of directors on the same day to review a proposal for using part of its own funds to purchase financial products [1] - The investment aims to improve the efficiency of fund utilization and rationally use idle self-owned funds, ensuring that normal operations of the company and its subsidiaries are not affected [1] - The total investment amount is proposed to be no more than 5 billion RMB, with the idle self-owned funds being available for cyclical use during the investment period [1]

Core Viewpoint - Kanglong Chemical (03759) reported a revenue of 14.095 billion RMB for the year ending December 31, 2025, representing a year-on-year growth of 14.8% [1] Financial Performance - The profit attributable to the company's shareholders was 1.664 billion RMB, a decrease of 7.2% year-on-year [1] - Basic earnings per share were 0.9443 RMB, with a proposed final dividend of 2.0 RMB per 10 shares (tax included) [1] Laboratory Services Segment - Revenue from laboratory services reached 8.1589 billion RMB, an increase of 15.8% compared to the previous year [1] - The gross margin for the laboratory services segment was 44.7%, up by 0.3 percentage points year-on-year [1] - New orders in this segment grew by approximately 12% year-on-year [1] Strategic Developments - In 2025, the company expanded multiple strategic partnerships and achieved breakthroughs in large collaborative projects [1] - The company leveraged its academic advantages and technical accumulation to achieve rapid development in new molecular drug research services [1] Workforce and Global Impact - As of December 31, 2025, the laboratory services workforce comprised 11,776 employees, including over 7,100 laboratory chemists, positioning the company as a leader in scale and experience in laboratory chemical services globally [1] - The laboratory services team participated in 887 global innovative drug discovery projects during the reporting period [1]